Advice

following a full submission:

eltrombopag (Revolade) is accepted for restricted use  within NHS Scotland.

Indication under review: Eltrombopag is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).  Eltrombopag may be considered as second-line treatment for adult non splenectomised patients where surgery is contraindicated.

SMC restriction: in both the splenectomised and non-splenectomised patient populations, restricted to use in patients with severe symptomatic ITP or a high risk of bleeding.

Eltrombopag has been shown to be significantly more effective than placebo in raising and maintaining platelet counts at (or above) a minimum target level in previously treated patients with ITP.

Download detailed advice98KB (PDF)

Download

Medicine details

Medicine name:
eltrombopag (Revolade)
SMC ID:
625/10
Indication:
Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published:
09 August 2010
Additional notes

The marketing authorisation for eltrombopag was extended to include use in adult non-splenectomised patients where surgery is not contra-indicated in February 2016. This minor licence change will not be assessed. The restriction to use in patients with severe symptomatic ITP or a high risk of bleeding still applies regardless of spleen status.